Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

419 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-02-29

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Binodenoson (an experimental drug) and adenosine (an FDA-approved drug that is currently used by doctors) are used to increase blood flow to the heart just like when a person exercises on a treadmill. Using imaging techniques, this increased blood flow can help determine if areas of the heart are not getting enough blood and oxygen during exercise. The purpose of the study is to determine if binodenoson is as good as adenosine in determining if there are areas of the heart not getting enough oxygen when blood flow to the heart is increased.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208299

Coronary Artery Disease

COMPLETED PHASE3

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

NCT00881218

Ischemic Heart Disease

COMPLETED EARLY_PHASE1

Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET

NCT01109992

Coronary Artery Disease

COMPLETED PHASE4

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

NCT03557385

Percutaneous Coronary Intervention

COMPLETED PHASE4

Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses

NCT06578234

Chronic Coronary Syndrome Coronary Artery Disease Ischemic Heart Disease

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

binodenoson then adenosine

binodenoson (experimental); adenosine (active comparator)

Group Type OTHER

binodenoson

Intervention Type DRUG

30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo

adenosine

Intervention Type DRUG

30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)

adenosine then binodenoson

adenosine (active comparator); binodenoson (experimental)

Group Type OTHER

binodenoson

Intervention Type DRUG

30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo

adenosine

Intervention Type DRUG

30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

binodenoson

30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo

Intervention Type DRUG

adenosine

30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CorVue

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to understand and sign an informed consent form.

Exclusion Criteria

* Women who are of childbearing potential.
* Very low likelihood of coronary artery disease (by American Heart Association and American College of Cardiology standards).
* Documented history of acute myocardial infarction within 30 days.
* Percutaneous coronary intervention or coronary bypass graft surgery within 3 years, unless typical or atypical anginal symptoms are present.
* Reactive airway disease or other contraindication that preclude a patient from receiving adenosine.
* Previous heart transplant or listed to receive a heart transplant.
* Cardiomyopathy (idiopathic dilated, restrictive, hypertrophic).
* History of hemodynamically significant supraventricular tachycardia or sustained ventricular tachycardia.
* Presence of second- or third-degree AV block (in the absence of permanent pacemaker).
* Left ventricular ejection fraction greater than 35%, known prior to the first imaging procedure.
* Presence of advanced heart failure, New York Heart Association Class IV.
* History of vasospastic/Prinzmetal angina.
* Active (under treatment) cancer (except skin cancers).
* Inability to discontinue antianginal medications, Aggrenox®, dipyridamole, and xanthine-containing drugs and foods (including caffeine) as required prior to each imaging procedure.
* Previous participation in a study of binodenoson.
* Any physical or psychosocial condition that, based on the Investigator's judgment, would prevent the patient from completing the study.

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No